Xilio Therapeutics Announces Inducement Grants Under聽Nasdaq Listing Rule 5635(c)(4)
Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, has granted stock options to two new employees effective July 1, 2025. The inducement grants include options to purchase 10,700 shares of common stock at an exercise price of $0.693 per share.
The stock options have a ten-year term with a vesting schedule of 25% after the first year and the remaining 75% vesting monthly over three years. These grants were made under Xilio's 2022 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Xilio Therapeutics (Nasdaq: XLO), un'azienda biotecnologica in fase clinica specializzata in terapie immuno-oncologiche attivate dai tumori, ha concesso opzioni su azioni a due nuovi dipendenti a partire dal 1掳 luglio 2025. Le concessioni incentivanti includono opzioni per acquistare 10.700 azioni ordinarie al prezzo di esercizio di 0,693 $ per azione.
Le opzioni hanno una durata di dieci anni con un piano di maturazione che prevede il 25% dopo il primo anno e il restante 75% che matura mensilmente nei successivi tre anni. Queste concessioni sono state effettuate nell'ambito del Piano di Incentivi Azionari 2022 di Xilio, in conformit脿 con la Regola di Quotazione Nasdaq 5635(c)(4).
Xilio Therapeutics (Nasdaq: XLO), una empresa biotecnol贸gica en etapa cl铆nica enfocada en terapias inmunooncol贸gicas activadas por tumores, ha otorgado opciones sobre acciones a dos nuevos empleados con efecto a partir del 1 de julio de 2025. Las concesiones por inducci贸n incluyen opciones para comprar 10,700 acciones ordinarias a un precio de ejercicio de $0.693 por acci贸n.
Las opciones tienen un plazo de diez a帽os con un calendario de adquisici贸n del 25% despu茅s del primer a帽o y el 75% restante que se adquiere mensualmente durante los siguientes tres a帽os. Estas concesiones se realizaron bajo el Plan de Incentivos de Acciones por Inducci贸n 2022 de Xilio, de acuerdo con la Regla de Cotizaci贸n Nasdaq 5635(c)(4).
Xilio Therapeutics (雮橃姢雼�: XLO)電� 膦呾枒 頇滌劚頇� 氅挫棴頃晹 旃橂鞝滌棎 欷戩爯鞚� 霊� 鞛勳儊 雼硠鞚� 靸濍獏瓿淀暀 須岇偓搿�, 2025雲� 7鞗� 1鞚茧秬搿� 霊� 氇呾潣 鞁犾瀰 歆侅洂鞐愱矊 欤检嫕 毵れ垬靹犿儩甓岇潉 攵�鞐枅鞀惦媹雼�. 鞚胳劶韹半笇 攵�鞐棎電� 10,700欤�鞚� 氤错喌欤茧ゼ 欤茧嫻 0.693雼煬鞚� 頄夓偓 臧�瓴╈溂搿� 甑Г頃� 靾� 鞛堧姅 鞓奠厴鞚� 韽暔霅╇媹雼�.
鞚� 欤检嫕 毵れ垬靹犿儩甓岇潃 10雲勱皠 鞙犿毃頃橂┌, 1雲� 頉� 25%臧� 氩犾姢韺呺悩瓿� 雮橂ǜ歆� 75%電� 3雲勳棎 瓯胳硱 毵れ洈 氩犾姢韺呺惄雼堧嫟. 鞚� 攵�鞐姅 雮橃姢雼� 靸侅灔 攴滌箼 5635(c)(4)鞐� 霐半澕 Xilio鞚� 2022雲� 鞚胳劶韹半笇 欤检嫕 瓿勴殟 頃橃棎 鞚措（鞏挫鞀惦媹雼�.
Xilio Therapeutics (Nasdaq : XLO), une soci茅t茅 de biotechnologie en phase clinique sp茅cialis茅e dans les th茅rapies immuno-oncologiques activ茅es par les tumeurs, a accord茅 des options d'achat d'actions 脿 deux nouveaux employ茅s 脿 compter du 1er juillet 2025. Les attributions incitatives comprennent des options d'achat de 10 700 actions ordinaires au prix d'exercice de 0,693 $ par action.
Les options d'achat ont une dur茅e de dix ans avec un calendrier d'acquisition de 25 % apr猫s la premi猫re ann茅e et les 75 % restants acqu茅rant mensuellement sur trois ans. Ces attributions ont 茅t茅 effectu茅es dans le cadre du Plan d'Incitation 脿 l'Attribution d'Actions 2022 de Xilio, conform茅ment 脿 la r猫gle de cotation Nasdaq 5635(c)(4).
Xilio Therapeutics (Nasdaq: XLO), ein biotechnologisches Unternehmen in der klinischen Phase mit Fokus auf tumoraktivierte Immunonkologie-Therapien, hat zwei neuen Mitarbeitern zum 1. Juli 2025 Aktienoptionen gew盲hrt. Die Anreizzuteilungen umfassen Optionen zum Kauf von 10.700 Stammaktien zu einem Aus眉bungspreis von 0,693 $ pro Aktie.
Die Aktienoptionen haben eine Laufzeit von zehn Jahren mit einem Vesting-Plan, der 25 % nach dem ersten Jahr und die restlichen 75 % monatlich 眉ber drei Jahre vorsieht. Diese Zuteilungen erfolgten im Rahmen von Xilios Inducement Stock Incentive Plan 2022 gem盲脽 der Nasdaq-Listing-Regel 5635(c)(4).
- None.
- None.
WALTHAM, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective July 1, 2025, the company granted non-qualified stock options to purchase 10,700 shares of its common stock to two new employees under Xilio Therapeutics鈥� 2022 Inducement Stock Incentive Plan.
The stock options have an exercise price of
The stock options are subject to the terms and conditions of Xilio Therapeutics鈥� 2022 Inducement Stock Incentive Plan, as well as the terms and conditions of the stock option agreement covering the grant and were made as an inducement material to the individual entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated, or masked, immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary platform to advance a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting聽聽and follow us on LinkedIn (.).
Investor and Media Contact:聽
Scott Young
Vice President, Investor Relations and Corporate Communications
FAQ
What stock options did Xilio Therapeutics (XLO) grant to new employees in July 2025?
What is the vesting schedule for XLO's July 2025 employee stock options?
What is the exercise price of Xilio Therapeutics' July 2025 inducement grants?
How long is the term of XLO's July 2025 employee stock options?
